SCHEMBL4550673

SCHEMBL4550673

CCC(N)(C(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HIF1A Q16665 1/20 0.51
TDP1 Q9NUW8 3/20 0.46
MAPK1 P28482 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KMT2A Q03164 2/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA9 Q16790 2/20 0.45
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7476437 1.00 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL8643594 1.00 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
Hydrochloric Acid SCHEMBL11265034 0.98 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL11265025 0.88 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL28362146 0.88 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL7440964 0.88 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL28366123 0.88 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL9073323 0.85 SMN1; SMN2 (0.68) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL7653623 0.85 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1
SCHEMBL8706009 0.85 SMN1; SMN2 (0.68) ALDH1A1SMN1; SMN2HIF1ATDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101031569-B Quinazolinones as human phosphatidylinositol 3-kinase delta inhibitors ICOS CORP 2011-06-22 CN disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
EP-1051176-B1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMA INC (US) 2006-11-22 EP disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed
CN-1420882-A Substd. oxoazaheterocyclyl compounds AVENTIS PHARM PROD INC (US) 2003-05-28 CN disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP disclosed
CN-1078204-C Amino acid amide derivative, agrohorticultural bactericide, and production process KUMIAI CHEMICAL INDUSTRY CO (JP) 2002-01-23 CN disclosed
EP-1079821-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2001-08-29 EP disclosed
CN-1291892-A Substituted oxoazaheterocyclyl factor Xa inhibitors AWENTIS PHARMACEUTICAL INC (US) 2001-04-18 CN disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed
US-5726185-A BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELET AGGREGATION AND CELL TO CELL ADHESION HOFFMANN-LA ROCHE INC. (US) 1998-03-10 US disclosed
WO-1997016433-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-05-09 WO disclosed
CN-1108863-A Amino acid amide derivative, agrohorticultural bactericide, and production process KUMIAI CHEMICAL INDUSTRY CO (JP) 1995-09-20 CN disclosed
WO-1995022330-A1 ANTIVIRAL AGENTS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1995-08-24 WO disclosed
US-4299767-A ANTIALDOSTERONES, HYPOTENSIVE AGENTS, TREATMENT OF HEART AND LEVER DISORDERS HOFFMANN-LA ROCHE INC. (US) 1981-11-10 US disclosed
US-4296031-A ALDOSTERONE ANTAGONIST HOFFMANN-LA ROCHE INC. (US) 1981-10-20 US disclosed
US-4294758-A ANTICHOLESTEROL AGENTS, CARDIOVASCULAR DISORDERS HOFFMANN-LA ROCHE INC. (US) 1981-10-13 US disclosed
US-4281188-A ANTIALDOSTERONES HOFFMANN-LA ROCHE INC. (US) 1981-07-28 US disclosed
US-4251443-A ALDOSTERONE ANTAGONISTS; PREVENTION OF HEART FAILURE, HEPATIC ASCITES, ALDOSTERONISM, HYPERTENSION HOFFMANN-LA ROCHE INC. (US) 1981-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 ALDH1A1 3776/4885SMN1; SMN2 4142/4885HIF1A 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.